{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:33Z","timestamp":1787002653281,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41397-018-0025-5","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T12:40:15Z","timestamp":1526906415000},"page":"528-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients"],"prefix":"10.1038","volume":"18","author":[{"name":"on behalf of the MATURA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2518-5799","authenticated-orcid":false,"given":"John C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and PAMERA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Consortia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bongartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borbala","family":"Mifsud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-6585","authenticated-orcid":false,"given":"Athina","family":"Spiliopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Twigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Freeston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie L.","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Cordell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna L.","family":"Strathdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Arnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. H.","family":"de Hair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P.","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Aslibekyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald F.","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-5670","authenticated-orcid":false,"given":"Leonid","family":"Padyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Louis","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Cope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M. M.","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9097-7381","authenticated-orcid":false,"given":"Michael R.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Agakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McKeigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisei","family":"Mushiroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weinshilboum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3316-2527","authenticated-orcid":false,"given":"Anne","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-624X","authenticated-orcid":false,"given":"Ann W.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-7724","authenticated-orcid":false,"given":"Jennifer H.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"key":"25_CR1","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68:1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrrheum.2009.182","volume":"5","author":"RF Vollenhoven van","year":"2009","unstructured":"van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5:531\u201341.","journal-title":"Nat Rev Rheumatol"},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631\u20137.","journal-title":"Ann Rheum Dis"},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/ard.2009.123976","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis. 2010;69:638\u201343.","journal-title":"Ann Rheum Dis"},{"key":"25_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75:16\u201322.","journal-title":"Ann Rheum Dis"},{"key":"25_CR6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics R. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558\u201365.","journal-title":"Rheumatology (Oxford)"},{"key":"25_CR7","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1002\/art.22129","volume":"54","author":"T Dervieux","year":"2006","unstructured":"Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095\u2013103.","journal-title":"Arthritis Rheum"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/rheumatology\/ken513","volume":"48","author":"YC Lee","year":"2009","unstructured":"Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford). 2009;48:613\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00228-012-1341-3","volume":"69","author":"B Jekic","year":"2013","unstructured":"Jekic B, Lukovic L, Bunjevacki V, Milic V, Novakovic I, Damnjanovic T, et al. Association of the TYMS 3G\/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol. 2013;69:377\u201383.","journal-title":"Eur J Clin Pharmacol"},{"key":"25_CR10","first-page":"368681","volume":"2014","author":"A Lima","year":"2014","unstructured":"Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V, et al. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. Biomed Res Int. 2014;2014:368681.","journal-title":"Biomed Res Int"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrrheum.2014.16","volume":"10","author":"D Plant","year":"2014","unstructured":"Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol. 2014;10:329\u201337.","journal-title":"Nat Rev Rheumatol"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/art.38331","volume":"66","author":"TN Kung","year":"2014","unstructured":"Kung TN, Dennis J, Ma Y, Xie G, Bykerk V, Pope J, et al. RFC1 80G A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. Arthritis Rheumatol. 2014;66:1111\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"25_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FPC.0000000000000036","volume":"24","author":"S Senapati","year":"2014","unstructured":"Senapati S, Singh S, Das M, Kumar A, Gupta R, Kumar U, et al. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet Genomics. 2014;24:211\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/tpj.2014.3","volume":"14","author":"J Cobb","year":"2014","unstructured":"Cobb J, Cule E, Moncrieffe H, Hinks A, Ursu S, Patrick F, et al. Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharmacogenomics J. 2014;14:356\u201364.","journal-title":"Pharmacogenomics J"},{"key":"25_CR15","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/rheumatology\/kew369","volume":"56","author":"A Barton","year":"2016","unstructured":"Barton A, Pitzalis C. Stratified medicine in rheumatoid arthritis-the MATURA programme. Rheumatology (Oxford). 2016;56:1247\u201350.","journal-title":"Rheumatology (Oxford)"},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/keq178","volume":"49","author":"PG Conaghan","year":"2010","unstructured":"Conaghan PG, Hensor EM, Keenan AM, Morgan AW, Emery P, Consortium Y. Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Rheumatology (Oxford). 2010;49:1894\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"25_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/annrheumdis-2016-209713","volume":"75","author":"JC Sergeant","year":"2016","unstructured":"Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Barton A, et al. OP0013\u2005prediction of non-response to methotrexate therapy in the Rheumatoid Arthritis Medication Study (RAMS). Ann Rheum Dis. 2016;75:57\u201358.","journal-title":"Ann Rheum Dis"},{"key":"25_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-0915-0","volume":"17","author":"RB Dumitru","year":"2016","unstructured":"Dumitru RB, Horton S, Hodgson R, Wakefield RJ, Hensor EM, Emery P, et al. A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). BMC Musculoskelet Disord. 2016;17:61.","journal-title":"BMC Musculoskelet Disord"},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75\u201385.","journal-title":"Ann Rheum Dis"},{"key":"25_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/annrheumdis-2013-204882","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014;73:1027\u201336.","journal-title":"Ann Rheum Dis"},{"key":"25_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/ard.2007.076299","volume":"67","author":"EH Choy","year":"2008","unstructured":"Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis. 2008;67:656\u201363.","journal-title":"Ann Rheum Dis"},{"key":"25_CR22","first-page":"88","volume":"34","author":"IC Scott","year":"2016","unstructured":"Scott IC, Ibrahim F, Simpson G, Kowalczyk A, White-Alao B, Hassell A, et al. A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:88\u201393.","journal-title":"Clin Exp Rheumatol"},{"key":"25_CR23","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.34498","volume":"64","author":"LW Moreland","year":"2012","unstructured":"Moreland LW, O\u2019Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824\u201335.","journal-title":"Arthritis Rheum"},{"key":"25_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","volume":"374","author":"RF Vollenhoven van","year":"2009","unstructured":"van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374:459\u201366.","journal-title":"Lancet"},{"key":"25_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/art.33348","volume":"64","author":"MJ Hair de","year":"2012","unstructured":"de Hair MJ, Lehmann KA, van de Sande MG, Maijer KI, Gerlag DM, Tak PP. The clinical picture of rheumatoid arthritis according to the 2010 American College of Rheumatology\/European League Against Rheumatism criteria: Is this still the same disease? Arthritis Rheum. 2012;64:389\u201393.","journal-title":"Arthritis Rheum"},{"key":"25_CR26","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/art.39627","volume":"68","author":"C Kronisch","year":"2016","unstructured":"Kronisch C, McLernon DJ, Dale J, Paterson C, Ralston SH, Reid DM, et al. Brief report: predicting functional disability: one-year results from the Scottish Early Rheumatoid Arthritis Inception Cohort. Arthritis Rheumatol. 2016;68:1596\u2013602.","journal-title":"Arthritis Rheumatol"},{"key":"25_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88\u201396.","journal-title":"Ann Rheum Dis"},{"key":"25_CR28","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629\u201335.","journal-title":"Ann Rheum Dis"},{"key":"25_CR29","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","volume":"49","author":"A Rubbert-Roth","year":"2010","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683\u201393.","journal-title":"Rheumatology (Oxford)"},{"key":"25_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.2010.137703","volume":"70","author":"PP Tak","year":"2011","unstructured":"Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39\u201346.","journal-title":"Ann Rheum Dis"},{"key":"25_CR31","doi-asserted-by":"publisher","first-page":"e87379","DOI":"10.1371\/journal.pone.0087379","volume":"9","author":"P Emery","year":"2014","unstructured":"Emery P, Rigby W, Tak PP, Dorner T, Olech E, Martin C, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS ONE. 2014;9:e87379.","journal-title":"PLoS ONE"},{"key":"25_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng0508-491","volume":"40","author":"D Reich","year":"2008","unstructured":"Reich D, Price AL, Patterson N. Principal component analysis of genetic data. Nat Genet. 2008;40:491\u20132.","journal-title":"Nat Genet"},{"key":"25_CR33","doi-asserted-by":"publisher","first-page":"e1000529","DOI":"10.1371\/journal.pgen.1000529","volume":"5","author":"BN Howie","year":"2009","unstructured":"Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5:e1000529.","journal-title":"PLoS Genet"},{"key":"25_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ajhg.2013.09.002","volume":"93","author":"O Delaneau","year":"2013","unstructured":"Delaneau O, Howie B, Cox AJ, Zagury JF, Marchini J. Haplotype estimation using sequencing reads. Am J Hum Genet. 2013;93:687\u201396.","journal-title":"Am J Hum Genet"},{"key":"25_CR35","doi-asserted-by":"crossref","unstructured":"Spiliopoulou A, Colombo M, Orchard P, Agakov F, McKeigue P. GeneImp: fast imputation to large reference panels using genotype likelihoods from ultra-low coverage sequencing. Genetics. 2017;91\u2013104.","DOI":"10.1534\/genetics.117.200063"},{"key":"25_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559\u201375.","journal-title":"Am J Hum Genet"},{"key":"25_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ng2088","volume":"39","author":"J Marchini","year":"2007","unstructured":"Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet. 2007;39:906\u201313.","journal-title":"Nat Genet"},{"key":"25_CR38","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"25_CR39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","volume":"21","author":"TS Mikkelsen","year":"2011","unstructured":"Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011;21:679\u201386.","journal-title":"Pharmacogenet Genomics"},{"key":"25_CR40","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/ng.2007.27","volume":"39","author":"RM Plenge","year":"2007","unstructured":"Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 2007;39:1477\u201382.","journal-title":"Nat Genet"},{"key":"25_CR41","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1002\/art.23623","volume":"58","author":"A Julia","year":"2008","unstructured":"Julia A, Ballina J, Canete JD, Balsa A, Tornero-Molina J, Naranjo A, et al. Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility. Arthritis Rheum. 2008;58:2275\u201386.","journal-title":"Arthritis Rheum"},{"key":"25_CR42","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376\u201381.","journal-title":"Nature"},{"key":"25_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jdermsci.2009.10.002","volume":"56","author":"H Kataoka","year":"2009","unstructured":"Kataoka H. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J Dermatol Sci. 2009;56:148\u201353.","journal-title":"J Dermatol Sci"},{"key":"25_CR44","doi-asserted-by":"crossref","unstructured":"Rivera-Valentin RK, Hua YQ, Zhang Y, Lala N, Yang YW, Hughes DPM. Her-4 mediates anoikis resistance, chemoresistance, and metastatic potential in osteosarcoma. Cancer Res. 2014;74:(20 Suppl):Abstract nr A71.","DOI":"10.1158\/1538-7445.PEDCAN-A71"},{"key":"25_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/rheumatology\/keq344","volume":"50","author":"C Bansard","year":"2011","unstructured":"Bansard C, Lequerre T, Derambure C, Vittecoq O, Hiron M, Daragon A, et al. Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra). Rheumatology (Oxford). 2011;50:283\u201392.","journal-title":"Rheumatology (Oxford)"},{"key":"25_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10069","volume":"6","author":"P Martin","year":"2015","unstructured":"Martin P, McGovern A, Orozco G, Duffus K, Yarwood A, Schoenfelder S, et al. Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. Nat Commun. 2015;6:10069.","journal-title":"Nat Commun"},{"key":"25_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0992-2","volume":"17","author":"J Cairns","year":"2016","unstructured":"Cairns J, Freire-Pritchett P, Wingett SW, Varnai C, Dimond A, Plagnol V, et al. CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. Genome Biol. 2016;17:127.","journal-title":"Genome Biol"},{"key":"25_CR48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2119\/molmed.2011.00048","volume":"18","author":"YC Wang","year":"2012","unstructured":"Wang YC, Chiang EP. Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo. Mol Med. 2012;18:423\u201332.","journal-title":"Mol Med"},{"key":"25_CR49","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","volume":"90","author":"D Ellinghaus","year":"2012","unstructured":"Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636\u201347.","journal-title":"Am J Hum Genet"},{"key":"25_CR50","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ng.2770","volume":"45","author":"C International Multiple Sclerosis Ge","year":"2013","unstructured":"International Multiple Sclerosis Genetics C, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353\u201360.","journal-title":"Nat Genet"},{"key":"25_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaut.2016.12.006","volume":"78","author":"NL Fewings","year":"2017","unstructured":"Fewings NL, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, et al. The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis. J Autoimmun. 2017;78:57\u201369.","journal-title":"J Autoimmun"},{"key":"25_CR52","doi-asserted-by":"crossref","unstructured":"Jennewein C, Zacharowski K. Abstracts of Sepsis 2012. Paris, France. November 14-16, 2012. Crit Care. 2012;16 Suppl 3:P22.","DOI":"10.1186\/cc11731"},{"key":"25_CR53","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1016\/j.febslet.2015.07.048","volume":"589","author":"VGA Arciuch","year":"2015","unstructured":"Arciuch VGA, Tedesco L, Fuertes M, Arzt E. Role of RSUME in inflammation and cancer. FEBS Lett. 2015;589:3330\u20135.","journal-title":"FEBS Lett"},{"key":"25_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12460","volume":"7","author":"SK Sieberts","year":"2016","unstructured":"Sieberts SK, Zhu F, Garcia-Garcia J, Stahl E, Pratap A, Pandey G, et al. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016;7:12460.","journal-title":"Nat Commun"},{"key":"25_CR55","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1136\/annrheumdis-2014-205541","volume":"74","author":"M Umicevic Mirkov","year":"2015","unstructured":"Umicevic Mirkov M, Janss L, Vermeulen SH, van de Laar MA, van Riel PL, Guchelaar HJ, et al. Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:2183\u20137.","journal-title":"Ann Rheum Dis"},{"key":"25_CR56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel van","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van \u2018t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34\u201340.","journal-title":"Arthritis Rheum"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0025-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T16:59:25Z","timestamp":1684601965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-018-0025-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1038\/s41397-018-0025-5","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]},"assertion":[{"value":"5 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Paul P Tak is an employee and shareholder of GlaxoSmithKline; GSK has not been involved in this study. Jianmei Wang is an employee of Roche Products and Felix Agakov is an employee of Pharmatics Ltd., UK. Dr. Weinshilboum is a co-founder and stockholder in OneOme LLC, a Pharmacogenomics Decision Support Company. Paul Emery has undertaken clinical trials and provided expert advice to Pfizer, MSD, Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Lilly. The authors declare no conflict of interest with the content contained in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}